Neumora Therapeutics, Inc. has announced its financial results for the third quarter ended September 30, 2026, in a report filed on November 16, 2026. This update is crucial for the company as it reflects its operational health and strategic direction within the competitive biological products sector.

Neumora Therapeutics, Inc. operates in the biological products industry, classified under SIC code 2836. The company is listed on the Nasdaq under the ticker symbol NMRA. As a smaller reporting company, Neumora is committed to transparency and regulatory compliance, which is vital in the biotech field.

The filing includes details of the company's financial performance, stating, "On November 16, 2026, Neumora Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2026." The full press release related to these results is available as an exhibit in the filing.

This financial update may affect various stakeholders, including investors, analysts, and competitors in the biological products industry. As Neumora continues to navigate its market position, its financial performance will be closely monitored by those interested in the sector.

Looking ahead, further filings may provide additional insights into Neumora's strategic plans and financial health. The filing does not specify what happens next.

Company Overview and Background

Neumora Therapeutics, Inc. was formerly known as RBNC Therapeutics, Inc., having undergone a name change on September 29, 2021. The company is incorporated in Delaware and operates primarily from its headquarters located at 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472.

As of the date of this filing, Neumora is classified under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products, excluding diagnostic substances. This classification highlights the company's focus on developing innovative therapies in the biotechnology sector.

Financial Reporting Details

The filing indicates that the financial results for the third quarter of 2026 were formally announced on November 16, 2026, and the complete press release is included as Exhibit 99.1 in the filing. This press release is crucial for stakeholders as it provides a detailed overview of the company's financial performance and operational metrics during the specified period.

Neumora Therapeutics is also subject to the reporting requirements of the Securities Exchange Act of 1934, and as a smaller reporting company, it emphasizes its commitment to regulatory compliance and transparency in its financial disclosures.

Future Outlook

While the current filing does not provide specific projections or future strategies, it is expected that subsequent reports will shed light on Neumora's ongoing projects and potential developments in its product pipeline. Stakeholders are encouraged to monitor future filings for updates on the company's strategic initiatives and financial health.